Objective:
To evaluate the safety and efficacy of the photovoltaic retina implant microarray (PRIMA) system in restoring central vision in patients with advanced geographic atrophy (GA) due to age-related macular degeneration (AMD), compared to existing treatments.
Key Findings:
- 26 of 32 evaluable participants achieved a clinically meaningful improvement in visual acuity at 12 months (81%).
- Mean improvement in visual acuity was 0.49 logMAR (24.5 letters) with PRIMA glasses.
- Prosthetic central vision was detected in 30 of 32 participants at 12 months.
- Eighty-four percent of participants reported being able to read letters, numbers, or words at home with the device.
Interpretation:
The PRIMA system effectively restored central vision in patients with GA, demonstrating significant improvements in visual acuity and user satisfaction.
Limitations:
- The study did not assess changes in visual impairment using the IVI questionnaire.
- Serious adverse events were observed, primarily within the first two months postoperatively.
- Long-term follow-up data is needed to assess sustained efficacy and safety.
Conclusion:
The PRIMA system shows promise in restoring central vision in patients with advanced GA, with benefits outweighing procedural risks. Ongoing follow-up will assess long-term outcomes and further validate these findings.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
